MICAFUNGIN

The United States Food and Drug Administration (FDA) granted initial approval to Micafungin on 17 January 2005.

Micafungin is used to treat a range of serious fungal infections caused by specific types of fungi. It is indicated for the treatment of invasive candidiasis, including candidemia, intra-abdominal candidiasis, and infections of the esophagus caused by Candida species. Additionally, it is used for the treatment of invasive aspergillosis and to initiate empirical antifungal therapy in certain circumstances. It is also used in managing fever in patients with low white blood cell counts (neutropenic fever) often associated with chemotherapy.

Micafungin works by inhibiting the synthesis of a crucial component in the fungal cell wall called beta-glucan. This disruption weakens the structural integrity of the cell wall, leading to increased permeability and ultimately causing the death of the fungal cell.

Common side effects of Micafungin include nausea, vomiting, headache, elevated liver enzyme levels, rash, and pain at the injection site. In some cases, patients might experience diarrhea or itching. Serious side effects are rare but can include severe allergic reactions, infusion reactions during or after administration, and adverse effects on liver function.

Micafungin can cause severe hypersensitivity reactions in individuals with a known allergy to the medication or its components.This medication may affect liver function, leading to elevated liver enzyme levels. It can interact with other medications, affecting their metabolism or efficacy.

Seek immediate medical attention if you experience symptoms such as difficulty breathing, swelling, or rash after taking Micafungin. Regular monitoring of liver function is recommended during treatment.Inform your healthcare provider about all medications, supplements, and herbal products you are taking to prevent potential interactions.

Inform your healthcare provider of your complete medical history before commencing Micafungin, including any known allergies, liver disease, or other significant medical conditions. Liver function should be monitored regularly during treatment; report symptoms such as jaundice or abdominal pain to your healthcare provider promptly. During infusions, remain alert for signs of infusion reactions including fever or difficulty breathing. Patients with compromised immune systems, those receiving immunosuppressive medications, or those with renal impairment should discuss the risks and benefits of Micafungin with their healthcare provider. Consider your age and underlying medical conditions when evaluating suitability for treatment. Attendance at scheduled follow-up appointments is necessary to monitor progress and assess for potential adverse effects.

Flynn Pharma Ltd, Electronic Medicines Compendium (EMC), [Revised on 21 Sep 2022] [Accessed on 23rd August 2023], https://www.medicines.org.uk/emc/product/11840/pil#gref Astellas Pharma US, Inc., US Food & Drug Administration, [Revised on 7/2021] [Accessed on 23rd August 2023], / https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212125s000lbl.pdf Harry W. Lampiris, Daniel S. Maddix, Antifungal Agents, Lange’s Basic & Clinical Pharmacology, 14th Edition, 2018, 853-862.